This means that the expression of these MEK-associated genes was related to the ER signaling pathway level in patients with gynecologic cancers and may explain the limited responsiveness to endocrine therapy of ovarian, endometrial, and cervical cancer. The gene discussed is MAP2K7; the disease is female reproductive organ cancer.